Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS
· Delayed Price · Currency is USD
0.0170
+0.0020 (13.33%)
Apr 3, 2025, 4:00 PM EST
Emmaus Life Sciences Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 20.43 | 0.18 | 29.6 | 18.39 | 20.61 | 23.17 | Upgrade
|
| Revenue Growth (YoY) | -28.22% | -99.41% | 60.94% | -10.77% | -11.04% | 1.82% | Upgrade
|
| Cost of Revenue | 1.08 | - | 1.34 | 2.59 | 3.31 | 2.25 | Upgrade
|
| Gross Profit | 19.35 | 0.18 | 28.26 | 15.8 | 17.3 | 20.92 | Upgrade
|
| Selling, General & Admin | 18.64 | - | 23.53 | 20.66 | 19.32 | 18.54 | Upgrade
|
| Research & Development | 0.69 | - | 1.19 | 1.73 | 4.11 | 2.41 | Upgrade
|
| Operating Expenses | 19.33 | - | 24.72 | 22.39 | 23.43 | 20.95 | Upgrade
|
| Operating Income | 0.02 | - | 3.54 | -6.59 | -6.13 | -0.03 | Upgrade
|
| Interest Expense | -6.39 | - | -7.38 | -5.01 | -3.1 | -5.99 | Upgrade
|
| Interest & Investment Income | 0.59 | - | 0.68 | 0.68 | 0.76 | 0.3 | Upgrade
|
| Earnings From Equity Investments | -0.37 | - | -1.71 | -1.91 | -2.73 | -2.06 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.45 | - | -1.77 | -2.66 | -2.02 | 1.5 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.8 | - | 3.97 | 5.56 | -2.34 | 0.5 | Upgrade
|
| EBT Excluding Unusual Items | -3.9 | - | -2.67 | -9.93 | -15.56 | -5.77 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.54 | - | -0.3 | -0.13 | - | 7.67 | Upgrade
|
| Other Unusual Items | 0.86 | - | -0.82 | -0.5 | -0.37 | -0.93 | Upgrade
|
| Pretax Income | -3.59 | - | -3.79 | -10.57 | -15.92 | 0.97 | Upgrade
|
| Income Tax Expense | -0.09 | - | -0.06 | 0.06 | 0.03 | -0.38 | Upgrade
|
| Net Income | -3.5 | - | -3.73 | -10.63 | -15.95 | 1.35 | Upgrade
|
| Net Income to Common | -3.5 | - | -3.73 | -10.63 | -15.95 | 1.35 | Upgrade
|
| Shares Outstanding (Basic) | 61 | - | 53 | 49 | 49 | 49 | Upgrade
|
| Shares Outstanding (Diluted) | 61 | - | 53 | 49 | 49 | 49 | Upgrade
|
| Shares Change (YoY) | 18.10% | - | 7.41% | 0.38% | 0.73% | 15.71% | Upgrade
|
| EPS (Basic) | -0.06 | - | -0.07 | -0.21 | -0.32 | 0.03 | Upgrade
|
| EPS (Diluted) | -0.06 | - | -0.07 | -0.21 | -0.32 | 0.03 | Upgrade
|
| Free Cash Flow | -1.61 | - | -1.52 | -5.1 | -1.33 | -2.47 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | - | -0.03 | -0.10 | -0.03 | -0.05 | Upgrade
|
| Gross Margin | 94.70% | 100.00% | 95.47% | 85.93% | 83.93% | 90.30% | Upgrade
|
| Operating Margin | 0.09% | - | 11.96% | -35.81% | -29.73% | -0.14% | Upgrade
|
| Profit Margin | -17.11% | - | -12.61% | -57.78% | -77.37% | 5.85% | Upgrade
|
| Free Cash Flow Margin | -7.86% | - | -5.14% | -27.73% | -6.44% | -10.64% | Upgrade
|
| EBITDA | 0.04 | - | 3.57 | -6.53 | -6.07 | 0.03 | Upgrade
|
| EBITDA Margin | 0.20% | - | 12.07% | -35.52% | -29.45% | 0.12% | Upgrade
|
| D&A For EBITDA | 0.02 | - | 0.03 | 0.05 | 0.06 | 0.06 | Upgrade
|
| EBIT | 0.02 | - | 3.54 | -6.59 | -6.13 | -0.03 | Upgrade
|
| EBIT Margin | 0.09% | - | 11.96% | -35.81% | -29.73% | -0.14% | Upgrade
|
Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.